威斯津生物 focuses on the research, development, and commercialization of novel biopharmaceuticals. The company leverages advanced molecular biology techniques to create therapeutic candidates for unmet medical needs. Their pipeline targets complex diseases through innovative drug discovery platforms.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for Epstein-Barr virus (EBV)-related tumors and liver cancer often lack efficacy, and effective vaccines are needed to combat these diseases. Traditional drug development methods can be slow and may not fully optimize drug formulations for maximum therapeutic effect.
Solution
Weijin Biotech is developing mRNA-based therapeutics and vaccines to target EBV-related tumors and liver cancer. The company utilizes proprietary mRNA sequences and non-viral delivery vectors to enhance drug delivery and efficacy. Their approach includes optimizing drug formulations through machine learning and advanced lipid excipients. This technology aims to provide more effective treatments against cancer and infectious diseases.
Target Audience
The primary target audience includes patients with EBV-related tumors and liver cancer, as well as healthcare providers seeking innovative treatment options.
Features
- mRNA-based therapeutics and vaccines for EBV-related tumors and liver cancer
- Patented mRNA sequences for enhanced therapeutic effect
- Non-viral delivery vectors for efficient drug delivery
- Machine learning-driven optimization of drug formulations
- Advanced lipid excipients to improve drug stability and bioavailability
- Pipeline of over 20 mRNA drug and vaccine candidates, including viral vaccines, anti-tumor vaccines, and vaccines for aging and obesity
- Novel nano-adjuvants to enhance immune response